period does not mean that the price rise in the shares of Lupin was abnormal or that it was artificially ramped up during the said period. The appellants have produced records to show that there were many other pharmaceutical companies whose share prices were also rising significantly, some of them even at a faster pace, during the same period. Our pointed attention was drawn to the scrips of Arbindo Pharma, Ipca Lab, Nicholas Piramal, Orchid Chemicals and Pharma, Sun Pharma and Torrent Pharma. These are all medium size companies in the pharmaceutical sector which could be compared with Lupin. The share price of Arbindo Pharma on 01/09/1999 was around Rs. 560/- and on 30/12/1999 it had risen to Rs. 1234.55. There was an increase of 121.19% during this relevant period. Similarly share price of Torrent Pharma on 01/09/1999 was around Rs. 210.75 and on 30/12/1999 it closed at Rs. 585/- though during the course of the day it had touched Rs. 599.95. There was thus an increase of about 185% in the price. Similar is the case with the other companies. Shri N.H. Seervai, learned senior counsel appearing for the appellants was not wrong when he contended that the Board was in error in comparing the price of Lupin with big size companies and did not take note of the rising prices of the medium size companies with which Lupin could be better compared. From the various charts that he produced along with the compilation, the veracity of which could not be challenged by the respondent because all were computer printouts from the concerned exchanges, it is clear that the price of the shares of pharmaceutical companies was on the rise during the relevant period. It cannot therefore be said that the price of Lupin alone had